United StatesOpdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg per 20 mL (12 mg/mL and 4 mg/mL) single‑dose vial, NDC 0003-7125-11, Lot 033A23B, expiry 4/30/2026, distributed nationwide in the United States is affected. Bristol-Myers Squibb is recalling 12,778 vials due to lack of assurance of sterility.
What's being recalled
Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11
Recalling firm: Bristol-Myers Squibb Company, New Brunswick, NJ, United States.
How to identify it
Lot: 033A23B, Expiry: 4/30/2026
The hazard
Lack of Assurance of Sterility.
What to do
Don't stop taking a prescribed medicine without talking to your doctor or pharmacist first. For other products, stop using them and ask the pharmacist, seller or maker what to do.
The notice doesn't give instructions for consumers, so this is general advice for health & beauty recalls. Check the official notice for the details.
Where it was sold
Nationwide in the USA
The official notice
This page is a summary of the notice published by U.S. Food and Drug Administration (enforcement reports), collected from U.S. Food and Drug Administration (enforcement reports). Check the original before you act on it.
Read the official notice (opens in a new tab)